South Africa has made history by becoming the first African nation to register Lenacapavir, a revolutionary long-acting ...

SAHPRA chief executive Dr Boitumelo Semete-Makokotlela said the product is “the most effective HIV prevention measure thus ...

The timing of the renewed support is pivotal. South Africa is preparing to roll out Lenacapavir, a groundbreaking long-acting ...

South Africa’s Health Product Regulatory Authority (SAHPRA) has approved the use of the twice-yearly HIV prevention drug, lenacapavir. In a statement released on 27 October, the regulatory body said ...

SAHPRA has registered Lenacapavir, a new six-monthly PrEP injection to prevent HIV-1 in adults and adolescents over 35 kg.

By William Baloyi When President Donald Trump issued an executive order suspending all foreign aid to South Africa, in ...

KZN to receive Lenacapavir,new long-acting HIV prevention injection. Minister Motsoaledi confirms rollout to 360 clinics, for 6-month protection dose ...

South Africa has become the first African country, and our medicines regulator the third worldwide, to register the ...

The South African Health Products Regulatory Authority (SAHPRA) has announced the registration of lenacapavir, making South ...

Dr Joel Steingo of TB HIV Care says Lenacapavir could be a breakthrough in reducing infections, especially at a time when ...

HIV prevention drug Lenacapavir, which has been tested in South Africa during clinical trials, will be made available in the country in 2026 for high-risk groups.

The drug can be produced for as little as $25 per person annually, but even at $2000 per person, it can reduce new US infections almost entirely, a researcher says.